Cap

Zacks Small Cap Research – UHAL: Reports 3Q FY2025 Results: Demand for self-moving equipment rentals increases YOY for the 3rd consecutive quarter after seven quarters of single-digit declines. Self-Storage continues to deliver top-line growth. Record amount of self-storage rentable sq. ft. added in last 12 months. – Go Health Pro

by
Zacks Small Cap Research – UHAL: Reports 3Q FY2025 Results: Demand for self-moving equipment rentals increases YOY for the 3rd consecutive quarter after seven quarters of single-digit declines. Self-Storage continues to deliver top-line growth. Record amount of self-storage rentable sq. ft. added in last 12 months. – Go Health Pro

By Steven Ralston, CFA NYSE:UHAL READ THE FULL UHAL RESEARCH REPORT U-Haul Holding Company (NYSE:UHAL) reported financial results for 3Q FY2025 on February 5th. Total revenues increased 3.7% to approximately $1.39 billion, primarily due to stronger revenue growth of 4.6% in the self-moving equipment rental business, along with a 7.9% increase in theself-storage segment. In … Read more

Zacks Small Cap Research – TELO Improves Balance Sheet – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. … Read more

Zacks Small Cap Research – PLX: Revisiting the Thesis – Go Health Pro

by
Zacks Small Cap Research – PLX: Revisiting the Thesis – Go Health Pro

By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Reasons To Own / A Compelling Idea for 2025 Protalix Biotherapeutics, Inc. (NYSE:PLX) finds itself in an enviable position as we begin 2025. The company has two approved products generating revenues and a pipeline with multiple candidates in development. Its products are produced and … Read more

Zacks Small Cap Research – AEMD Treats First Patient in Australian Safety, Feasibility & Dose-Finding Clinical Trial of Hemopurifier – Go Health Pro

by
Zacks Small Cap Research – AEMD Treats First Patient in Australian Safety, Feasibility & Dose-Finding Clinical Trial of Hemopurifier – Go Health Pro

By M. Marin NASDAQ:AEMD Aethlon Medical (NASDAQ:AEMD) announced that the first patient in its Australian safety, feasibility and dose-finding clinical trial has been treated with the Hemopurifier. The trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment. In other words, the trial is evaluating the Hemopurifier … Read more

Zacks Small Cap Research – PBSV Released Earnings and Declares Dividend – Go Health Pro

by

By Brad Sorensen, CFA OTC:PBSV READ THE FULL PBSV RESEARCH REPORT Pharma-Bio Serv (OTC:PBSV) announced results for the year ended October 31, 2024. The headline revenue and earnings releases were below expectations quarter, but management issued comments regarding future prospects that have us optimistic that the trend of decreasing revenue will soon be reversed. Management … Read more

x